Glioma-derived plasminogen activator inhibitor-1 (PAI-1) regulates the recruitment of LRP1 positive mast cells
暂无分享,去创建一个
Voichita D. Marinescu | F. Pontén | B. Westermark | A. Smits | Ananya Roy | K. Forsberg-Nilsson | L. Uhrbom | A. Coum | E. Tchougounova | Jelena Põlajeva | Sven Nelander | Elena Tchougounova | Lene Uhrbom
[1] G. von Heijne,et al. Tissue-based map of the human proteome , 2015, Science.
[2] Hua Yu,et al. Revisiting STAT3 signalling in cancer: new and unexpected biological functions , 2014, Nature Reviews Cancer.
[3] M Brada,et al. High-grade glioma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. , 2014, Annals of oncology : official journal of the European Society for Medical Oncology.
[4] G. Reifenberger,et al. EANO guideline for the diagnosis and treatment of anaplastic gliomas and glioblastoma. , 2014, The Lancet. Oncology.
[5] G. Nilsson,et al. Glioma‐derived macrophage migration inhibitory factor (MIF) promotes mast cell recruitment in a STAT5‐dependent manner , 2014, Molecular oncology.
[6] F. Levi-Schaffer,et al. Mitochondrial STAT3 plays a major role in IgE-antigen-mediated mast cell exocytosis. , 2014, The Journal of allergy and clinical immunology.
[7] Tao Jiang,et al. Understanding high grade glioma: molecular mechanism, therapy and comprehensive management. , 2013, Cancer letters.
[8] P. May,et al. The low-density lipoprotein receptor-related protein 1 in inflammation , 2013, Current opinion in lipidology.
[9] A. Mazar,et al. The Apparent uPA/PAI-1 Paradox in Cancer: More than Meets the Eye , 2013, Seminars in Thrombosis & Hemostasis.
[10] C. Heldin,et al. Snail depletes the tumorigenic potential of glioblastoma , 2013, Oncogene.
[11] K. Suk,et al. Plasminogen activator inhibitor type 1 regulates microglial motility and phagocytic activity , 2012, Journal of Neuroinflammation.
[12] Caroline Kampf,et al. Production of Tissue Microarrays, Immunohistochemistry Staining and Digitalization Within the Human Protein Atlas , 2012, Journal of visualized experiments : JoVE.
[13] Douglas Hanahan,et al. Accessories to the Crime: Functions of Cells Recruited to the Tumor Microenvironment Prospects and Obstacles for Therapeutic Targeting of Function-enabling Stromal Cell Types , 2022 .
[14] I. Alafuzoff,et al. Mast Cell Accumulation in Glioblastoma with a Potential Role for Stem Cell Factor and Chemokine CXCL12 , 2011, PloS one.
[15] Paul J. Higgins,et al. PAI-1: An Integrator of Cell Signaling and Migration , 2011, International journal of cell biology.
[16] B. Westermark,et al. Forced expression of Sox21 inhibits Sox2 and induces apoptosis in human glioma cells , 2011, International journal of cancer.
[17] E. Tartour,et al. Immune infiltration in human tumors: a prognostic factor that should not be ignored , 2010, Oncogene.
[18] S. Gabriel,et al. Integrated genomic analysis identifies clinically relevant subtypes of glioblastoma characterized by abnormalities in PDGFRA, IDH1, EGFR, and NF1. , 2010, Cancer cell.
[19] O. Chinot,et al. High expression of cathepsin B and plasminogen activator inhibitor type-1 are strong predictors of survival in glioblastomas , 2009, Acta Neuropathologica.
[20] W. Weiss,et al. Cyclic GMP-dependent protein kinase II inhibits cell proliferation, Sox9 expression and Akt phosphorylation in human glioma cell lines , 2009, Oncogene.
[21] K. Khazaie,et al. Mast cells in tumor growth: angiogenesis, tissue remodelling and immune-modulation. , 2009, Biochimica et biophysica acta.
[22] Joshua M. Korn,et al. Comprehensive genomic characterization defines human glioblastoma genes and core pathways , 2008, Nature.
[23] C. Gladson,et al. New molecular targets in angiogenic vessels of glioblastoma tumours , 2008, Expert Reviews in Molecular Medicine.
[24] Bianca Sperl,et al. Stattic: a small-molecule inhibitor of STAT3 activation and dimerization. , 2006, Chemistry & biology.
[25] J. McMurray. A new small-molecule Stat3 inhibitor. , 2006, Chemistry & biology.
[26] C. Heldin,et al. Characterization of an imatinib-sensitive subset of high-grade human glioma cultures , 2006, Oncogene.
[27] D. Metcalfe,et al. Characterization of novel stem cell factor responsive human mast cell lines LAD 1 and 2 established from a patient with mast cell sarcoma/leukemia; activation following aggregation of FcepsilonRI or FcgammaRI. , 2003, Leukemia research.
[28] A. Kaye,et al. The role of the plasminogen activation cascade in glioma cell invasion: a review , 2003, Journal of Clinical Neuroscience.
[29] Peter Hufnagl,et al. Plasminogen activator inhibitor 1: physiological and pathophysiological roles. , 2002, News in physiological sciences : an international journal of physiology produced jointly by the International Union of Physiological Sciences and the American Physiological Society.
[30] A. V. van Zonneveld,et al. Molecular Analysis of Ligand Binding to the Second Cluster of Complement-type Repeats of the Low Density Lipoprotein Receptor-related Protein , 1997, The Journal of Biological Chemistry.
[31] R Core Team,et al. R: A language and environment for statistical computing. , 2014 .
[32] Michael Lim,et al. Mechanisms of local immunoresistance in glioma. , 2010, Neurosurgery clinics of North America.
[33] Y. Iwadate,et al. High serum level of plasminogen activator inhibitor-1 predicts histological grade of intracerebral gliomas. , 2008, Anticancer research.
[34] Hua Yu,et al. Tumour immunology: Crosstalk between cancer and immune cells: role of STAT3 in the tumour microenvironment , 2007, Nature Reviews Immunology.
[35] T. Willnow,et al. The low-density-lipoprotein receptor-related protein (LRP) is processed by furin in vivo and in vitro. , 1996, The Biochemical journal.